Twitter Feed
about 147 days ago
about 351 days ago
about 372 days ago
Human-Derived Biomaterials
Key performs on-demand custom biomaterial collections and also has commonly-used biomaterials in inventory for research use.
Custom Biomaterial Collections
Key performs cellular and blood-component collection services performed by highly trained professionals in accordance with customer protocols and tested to customer-specification.
Selection:
Key can also perform a wide variety of selections and purifications to
achieve the cell population or blood component in compliance with
customer specification.
Donors: Products can be
collected from qualified and consented “normal” donors, donor-patients
(for autologous cell therapies), or diseased donors.
Sources:
Key’s custom collection service can provide research and clinical-grade
products sourced from multiple sources including peripheral blood
(apheresis product), whole blood, bone marrow, and umbilical cord
blood. Products from other sources such as umbilical cord tissue,
placenta, adipose tissue, menstrual blood, etc are currently in
development.
Apheresis-Derived Products |
Whole Blood-Derived Products |
|
Platelets | Whole Blood |
|
Granulocytes (neutrophils) |
Red Blood Cells |
|
Leukocytes |
Leukocytes |
|
|
|
|
Mononuclear Cells (MNCs) |
Platelets |
|
Plasma |
||
Cryoprecipitated Anti-Hemophilic Factor |
||
Cryoprecipitate-Poor Plasma |
||
Plasma |
Serum (true off-the-clot) |
|
|
||
|
Key provides customers with high-quality, inventoried cells and blood
component products collected from a variety of sources, donors, and
purified to varying degrees.
Products: Key maintains a constant and growing supply of mononuclear cells and a wide variety of separated cell fractions (e.g., CD34, CD4, T-regs, etc) in standard cell concentrations.
Sources:
Products in inventory are derived from peripheral blood
(apheresis product), bone marrow, and umbilical cord
blood. Products from other sources such as umbilical
cord tissue, placenta, adipose tissue, menstrual blood, etc are
currently in development.
Twitter
LinkedIn